Altimmune, Inc is a biotechnology business based in the US. Altimmune shares (ALT) are listed on the NASDAQ and all prices are listed in US Dollars. Altimmune employs 43 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Altimmune
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ALT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Altimmune stock price (NASDAQ: ALT)Use our graph to track the performance of ALT stocks over time.
Altimmune shares at a glance
|Latest market close||$12.95|
|52-week range||$7.80 - $29.71|
|50-day moving average||$11.90|
|200-day moving average||$14.19|
|Wall St. target price||$24.86|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.16|
Buy Altimmune shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Altimmune stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Altimmune price performance over time
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||28.98%|
|3 months (2021-04-30)||-10.50%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
|Revenue TTM||$6.8 million|
|Gross profit TTM||$-25,324,291|
|Return on assets TTM||-18.43%|
|Return on equity TTM||-41.63%|
|Market capitalisation||$360.9 million|
TTM: trailing 12 months
Shorting Altimmune shares
There are currently 5.3 million Altimmune shares held short by investors – that's known as Altimmune's "short interest". This figure is 13.5% up from 4.6 million last month.
There are a few different ways that this level of interest in shorting Altimmune shares can be evaluated.
Altimmune's "short interest ratio" (SIR)
Altimmune's "short interest ratio" (SIR) is the quantity of Altimmune shares currently shorted divided by the average quantity of Altimmune shares traded daily (recently around 3.8 million). Altimmune's SIR currently stands at 1.4. In other words for every 100,000 Altimmune shares traded daily on the market, roughly 1400 shares are currently held short.
However Altimmune's short interest can also be evaluated against the total number of Altimmune shares, or, against the total number of tradable Altimmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Altimmune's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Altimmune shares in existence, roughly 140 shares are currently held short) or 0.1777% of the tradable shares (for every 100,000 tradable Altimmune shares, roughly 178 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Altimmune.
Find out more about how you can short Altimmune stock.
Altimmune share dividends
We're not expecting Altimmune to pay a dividend over the next 12 months.
Have Altimmune's shares ever split?
Altimmune's shares were split on a 1:30 basis on 13 September 2018. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Altimmune shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Altimmune shares which in turn could have impacted Altimmune's share price.
Altimmune share price volatility
Over the last 12 months, Altimmune's shares have ranged in value from as little as $7.8 up to $29.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Altimmune's is 1.2938. This would suggest that Altimmune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease. The company develops AdCOVID, a single-dose intranasal vaccine that is in Phase I clinical trial to protect against COVID-19; T-COVID, an intranasal immune modulating therapeutic candidate, which is in Phase I/II clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19; NasoShield, an anthrax vaccine product candidate that is in a Phase 1b trial; and NasoVAX, a recombinant intranasal vaccine product candidate, which completed Phase IIa clinical trial for the treatment of seasonal and pandemic use. It also focuses on developing ALT-801, a novel peptide-based dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis that is in Phase I clinical trial; and HepTcell, an immunotherapeutic product candidate, which is in Phase II clinical trial for patients chronically infected with the hepatitis B virus. Altimmune, Inc. has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. The company is headquartered in Gaithersburg, Maryland.
Stocks similar to Altimmune
Altimmune in the news
Interesting ALT Put And Call Options For March 2022
Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Jim Cramer’s Game Plan for This Week and the Start of Earnings Season
Frequently asked questionsWhat percentage of Altimmune is owned by insiders or institutions?
Currently 6.212% of Altimmune shares are held by insiders and 66.145% by institutions. How many people work for Altimmune?
Latest data suggests 43 work at Altimmune. When does the fiscal year end for Altimmune?
Altimmune's fiscal year ends in December. Where is Altimmune based?
Altimmune's address is: 910 Clopper Road, Gaithersburg, MD, United States, 20878 What is Altimmune's ISIN number?
Altimmune's international securities identification number is: US02155H2004 What is Altimmune's CUSIP number?
Altimmune's Committee on Uniform Securities Identification Procedures number is: 02155H101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert